ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep.

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

He also said the company had a solid base in machine learning and artificial intelligence, bolstered by billions of nights ...

ResMed is an innovation machine. Our ongoing investments of 6% to 7% of revenues ... the world leader in providing facial interfaces in the field of sleep health and breathing health and healthcare ...

ResMed, the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, has launched AirSense 11 in India. The company’s next-generation Continuous Positive ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

The Sleep and Breathing Health segment ... its integrated care capabilities. ResMed is known to leverage trends such as artificial intelligence (AI) and machine learning to bolster its product ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...